A Phase I/II Seamless Adaptive, Open label study to assess Safety, Tolerability, Radiation Dosimetry, Biodistribution, and diagnostic ability of a Novel 18F-labelled Tracer, SYN2, for Positron Emission Tomography in Myocardial Perfusion Imaging (SAFER) in Healthy Volunteers (phase I) and patients with suspected Coronary Artery Disease (phase II)
Latest Information Update: 21 Apr 2025
At a glance
- Drugs 18F synapsin 2 (Primary)
- Indications Coronary artery disease
- Focus Adverse reactions; First in man
- Acronyms SAFER
- Sponsors Synektik S.A
Most Recent Events
- 01 Apr 2025 Results of phase I study, published in the Journal of Nuclear Medicine.
- 26 May 2023 Status changed from recruiting to completed.
- 08 Feb 2022 New trial record